CD274 and cancer: Recently developed immunotherapies, which aim to block the PD-1/PD-L1 pathway using specific monoclonal antibodies, dramatically improve antitumor immune responses in various cancer types like skin cancer and non-small cell lung cancer (Zang and Allison, 2007; Topalian et al., 2012).